Analytical Data
-
Gene name
SSX9
- Application
-
Alternative Names
SSX9P; SSX9; Putative Protein SSX9
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7RTT3
-
Expression Region
1-188 aa
-
AA Sequence
MNGDDAFARR PRAGSQIPEK IQKAFDDIAK YFSKKEWEKM KSSEKIIYVY MKRKYEAMTK LGFKATLPPF MCNTGATDLQ GNDFDNDRNH RNQVERSQMT FGRLQGIFPK IMPKKPAEVG NDSKEVPEAS GLQNDGKQLC PPGKPTTSEK INKASGPKRG KHAWTHRLRE RKQLVIYEEI SDPEEDDE
-
Molecular Weight
21.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SSX9 is a member of the SSX family of cancer/testis antigens, which are typically expressed in germ cells and various cancers, but not in normal tissues. This unique expression pattern makes SSX9 a potential target for cancer immunotherapy, as it could provoke an immune response against tumors while sparing healthy cells. Recent studies have focused on the characterization and functions of SSX9 to understand its role in tumorigenesis and immune modulation. Researchers have investigated the protein's structure, interactions, and immunogenic properties, revealing that SSX9 can stimulate T-cell responses in cancer patients. This has important implications for developing novel therapeutic strategies, including personalized cancer vaccines and adoptive T-cell therapies targeting SSX9. Additionally, examining the expression of SSX9 in different cancer types could provide insights into its potential as a biomarker for cancer diagnosis and prognosis. Understanding the molecular mechanisms governing SSX9 expression and activity may lead to better therapeutic interventions and improved outcomes for patients with malignancies expressing this antigen. As research continues to unveil the complexities of SSX9, it stands at the forefront of cancer immunology and targeted therapy, offering hope for more effective treatments in the fight against cancer.
